Search Within

Thoracic Oncology

Formats
  1. Meeting Abstract (1709)
  2. Journal Article (1439)
  3. Review (82)
  4. Editorial (58)
  5. Book Section (35)
  6. Guidelines (25)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3394)
  2. Solid Tumor Oncology Division (3394)
  3. GSK Faculty (1071)
  4. Department of Pathology and Laboratory Medicine (809)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (662)
  6. Human Oncology and Pathogenesis Program (635)

More Groups

People
  1. Mark Kris (872)
  2. Alexander Drilon (637)
  3. Gregory Riely (605)
  4. Charles Rudin (495)
  5. Marc Ladanyi (418)
  6. Matthew Hellmann (412)

More People

Years
  1. 2025 (114)
  2. 2024 (271)
  3. 2023 (273)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (703)
  2. Journal of Thoracic Oncology (517)
  3. Annals of Oncology (278)
  4. Clinical Cancer Research (158)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (782)
  2. Elsevier Inc. (738)
  3. American Association for Cancer Research (386)
  4. Oxford University Press (352)
  5. Nature Publishing Group (156)
  6. Elsevier Science, Inc. (79)

More Publishers

Results (3394)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
    Meeting Abstract

    De Braud, F. G. M.; Siena, S.; Barlesi, F.; Drilon, A.; Simmons, B. P.; Huang, X.; Ye, C.; Doebele, R. C.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study
    Meeting Abstract

    Reckamp, K. L.; Akerley, W.; Calvo, E.; Clarke, J.; Edelman, M. J.; He, K.; Moreno, V.; Neal, J. W.; Owonikoko, T. K.; Patel, J. D.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
    Meeting Abstract

    Italiano, A.; Nanda, S.; Keating, K.; Childs, B. H.; Fellous, M.; Drilon, A.; Hyman, D. M.
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
    Meeting Abstract

    Drilon, A.; Rogers, E.; Zhai, D.; Deng, W.; Zhang, X.; Lee, D.; Ung, J.; Whitten, J.; Zhang, H.; Liu, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
    Meeting Abstract

    Hyman, D. M.; Tan, D. S. W.; van Tilburg, C. M.; Albert, C. M.; Geoerger, B.; Farago, A. F.; Laetsch, T. W.; Kummar, S.; Doz, F.; Lassen, U. N.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours
    Meeting Abstract

    Govindan, R.; Fakih, M. G.; Price, T. J.; Falchook, G. S.; Desai, J.; Kuo, J. C.; Strickler, J. H.; Krauss, J. C.; Li, B. T.; Denlinger, C. S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety profile of tepotinib in patients with advanced solid tumors: Pooled analysis of phase I and II data
    Meeting Abstract

    Decaens, T.; Ryoo, B. Y.; Falchook, G. S.; Veillon, R.; Doi, T.; Yamazaki, K.; Hong, D.; Qin, S.; Scheele, J.; Bruns, R.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumours
    Meeting Abstract

    Schram, A. M.; Drilon, A.; Macarulla Mercade, T.; O'Reilly, E. M.; Rodon, J. A.; Wolpin, B. M.; Ou, S. H. I.; Kim, D. W.; Yang, J. C. H.; Lam, Y. C. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • KEYNOTE-495/KeyImPaCT: A randomized, biomarker-directed, phase II trial of pembrolizumab-based therapy for non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Gutierrez, M.; Lam, W. S.; Hellmann, M. D.; Gubens, M. A.; Aggarwal, C.; Tan, D. S. W.; Felip, E.; Chiu, J. W. Y.; Lee, J. S.; Yang, J. C. H.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1/TRK fusion-positive solid tumors (TRIDENT-1 study)
    Meeting Abstract

    Drilon, A.; Cho, B. C.; Kim, D. W.; Lee, J.; Lin, J. J.; Zhu, V.; Camidge, R. D.; Stopatschinskaja, S.; Cui, J. J.; Hyman, D. M.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save